Xilio Therapeutics, Inc. (XLO) Misses Q3 EPS by 6c

Xilio Therapeutics, Inc. (NASDAQ: XLO) reported Q3 EPS of ($0.11), $0.06 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $19.07 million versus the consensus estimate of $16.48 million.

For earnings history and earnings-related data on Xilio Therapeutics, Inc. (XLO) click here.

You May Also Be Interested In

• Medtronic jumps on earnings beat and raised guidance
• Edison Int'l (EIX) call put ratio 2.1 calls to 1 put as share price up 8.6%
• NIO (NIO) PT Lowered to $7.10 at Citi